Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study

Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study is a phase 3, randomised interventional study registered as NCT07020247 by West China Hospital, with a registry enrolment figure of 184 participants, started 2024-11-19 and due to reach its primary completion in 2027-07-31. Interventions recorded: Anti-PD-1 antibody drug named Serplulimab; Radiotherapy; Chemotherapy. Conditions listed: Locally Advanced Rectal Cancer (LARC); Immunotherapy; Radiotherapy; Total Neoadjuvant Therapy; Anal Function Preservation. Primary outcome: Complete response rate. Colorectal eligibility wording from the registry: "Patients with stage II/III rectal cancer staged under MRI or endoscopic ultrasonography and have at least one risk factor: cT4a and invasion of intestinal lumen for more than 1/2 week (measured by MRI)；cT4b(resectable)；cT3c-d with EMVI+ (upper middle rectum)；cN2；MRF+ (≤2mm)；lower rectal cancer is lo". Sites: China. No results are recorded here; the registry entry is the source.